Results 161 to 170 of about 2,331,898 (261)

Illuminating the black box: Mapping the fates of polymeric micelle drug carriers <i>in vivo</i>. [PDF]

Acta Pharm Sin B
Ding X.
europepmc   +1 more source

Recent progress in nanotechnology-based drug carriers for resveratrol delivery. [PDF]

Drug Deliv, 2023
Li C, Wang Z, Lei H, Zhang D.
europepmc   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Insights on the Generation of Polymeric Drug Carriers via Supercritical Fluid-Assisted Technologies. [PDF]

Materials (Basel)
Zanotti A, Cardea S.
europepmc   +1 more source

Functionalization of Hemoglobin Microparticles as drug carriers for more specific and effective cancer cell targeting

FUNCTIONALIZATION OF HEMOGLOBIN MICROPARTICLES AS DRUG CARRIERS FOR MORE SPECIFIC AND EFFECTIVE CANCER CELL TARGETING Functionalization of Hemoglobin Microparticles as drug carriers for more specific and effective cancer cell targeting / Müller-de Ahna,
Müller-de Ahna, Anna Maxine
core  

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

The Status of Extracellular Vesicles as Drug Carriers and Therapeutics. [PDF]

Nat Rev Bioeng
Chaudhari AP, Budayr OM, Bonacquisti EE, Kussatz CC, Bannon MS, Law KJ, Liu Y, Bolton ML, Glassman PM, Huang L, Nguyen J.   +10 more
europepmc   +1 more source

Polymer-lipid hybrid nanoparticles as potential lipophilic anticancer drug carriers. [PDF]

Discov Nano, 2023
Salel S, Iyisan B.
europepmc   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source

Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy

Molecular Oncology, EarlyView.
We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley   +1 more source